DUBLIN , Nov. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS): IRISH TAKEOVER PANEL OPENING POSI...


    

    
	
    




	
	
	
	
	
	
	
		
		
			
			
				
 
  
    
    
    
    
    
          
		  
          
            
            
             ,  /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS):
 IRISH TAKEOVER PANEL 
 OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 
 1.     KEY INFORMATION 

    
    
      
         (a)     
         Full name of discloser:    
        Alkermes plc   
      
      
         (b)     
         Owner or controller of interests and short  positions disclosed, if different from 1(a):      The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    
        N/A   
      
      
         (c)    
         Name of offeror/offeree in relation to whose  relevant securities this form relates:      Use a separate form for each offeror/offeree    
        Avadel Pharmaceuticals plc   
      
      
         (d)    
         Is the discloser the offeror or the offeree?    
        OFFEROR   
      
      
         (e)      
         Date position held:      The latest practicable date prior to the disclosure    
        3 November 2025   
      
      
         (f)       
         In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?      If it is a cash offer or possible cash offer, state  "N/A"    
        N/A   
      
    
   
  
 2.     INTERESTS AND SHORT POSITIONS 
 If there are interests and positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security. 
 Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates (Note 1)
N/A
 All interests and all short positions should be disclosed. 
 Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8. 
 3.     INTERESTS AND SHORT POSITIONS OF PERSONS ACTING         IN CONCERT WITH THE PARTY MAKING THE DISCLOSURE 

    
    
      
         Details of any interests and short positions (including directors'  and other employee options) of any person acting in concert with  the party making the disclosure:    
      
      
        Interests of J.P. Morgan (together with its members of staff under Rule 3.3(b)(v) of Part A of the Irish Takeover Rules), financial advisors to Alkermes plc, but, for clarity, not held on behalf of Alkermes plc:   
      
      
         
          Party     
          Class of Relevant Security     
          Number of ordinary shares held at midnight (ET) on 3 November 2025     
          Percentage of total issued share capital (rounded)     
      
      
         
        55I, LLC   
        Ordinary shares of US$0.01 each   
        53   
        0.0001 %   
      
      
         
        JPMorgan Chase Bank, National Association   
        Ordinary shares of US$0.01 each   
        13,500   
        0.0139 %   
      
      
         
        TOTAL   
         
        13,553   
        0.0139 %   
      
      
         
         
      
      
         
         
      
      
         
      
      
         Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.    
      
    
   
  
 Ap11 
 4.      OTHER INFORMATION 
 (a)     Indemnity and other dealing arrangements 

    
    
      
         Details of any indemnity or option arrangement, or any agreement  or understanding, formal or informal, relating to relevant securities  which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:    
      
      
         Irrevocable commitments and letters of intent should not be included. If  there are no such agreements, arrangements or understandings, state  "none"    
      
      
          None     
      
    
   
  
 (b)      Agreements, arrangements or understandings           relating to options or derivatives 

    
    
      
         Full details of any agreement, arrangement or understanding  between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.     
      
      
          None     
      
    
   
  
 (c)      Attachments 

    
    
      
         Is a Supplemental Form 8 attached?       
         YES/NO    
      
      
         
            No    
      
      
         
         
      
      
         Date of disclosure:    
        5 November 2025   
      
      
         Contact name:    
        Sandy Coombs, Alkermes   
      
      
         Telephone number:    
        +1 781 609 6377   
      
      
         
         
      
      
         Public disclosures under Rule 8.1 of the Rules must be made to a Regulatory Information Service.    
      
    
   
  
 Ap12 
 NOTES ON FORM 8.1(a) and (b) 
 
       See the definition of "interest in a relevant security" in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) of Part B of the Rules.  
       See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules.  
       If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.   For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.  References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022. 

SOURCE Alkermes plc

          
        

  
  
  
  

    
      
    
          
	Also from this source
	
		
			
				
									
										

										
									
								
			
				
									
										

										
									
								
			
		
		
	

        
  
  
  
  
  
  

			
			
			
		
		
	

  

ALKS

FORM 8.1(a) & (b) (Opening Position Disclosure)

Alkermes disclosed its position in the Irish Takeover Panel.
Avadel Pharmaceuticals is the relevant offeree in the disclosure.
J.P. Morgan acts as financial advisors for Alkermes.
Minor interests held by advisors revealed in the disclosure.
Disclosure date is November 5, 2025.

FORM 8.1(a) & (b) (Opening Position Disclosure)

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News